Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Number of antibodies encoded by virus.

No definition available.

Name:	vygr_AntibodiesEncodedByVirus
Namespace Prefix:	vygr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

Number of antibodies.

No definition available.

Name:	vygr_CollaborativeArrangementAntibodies
Namespace Prefix:	vygr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

Represents the amount of first research compound payment to be received under collaborative arrangements.

No definition available.

Name:	vygr_CollaborativeArrangementFirstResearchCompoundPaymentToBeReceived
Namespace Prefix:	vygr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The amount of milestone payments to be received for licensed compound in case of Alzheimer disease indication.

No definition available.

Name:	vygr_CollaborativeArrangementMilestonePaymentsToBeReceivedForLicensedCompoundInCaseOfAlzheimerDiseaseIndication
Namespace Prefix:	vygr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The amount of milestone payments to be received for licensed compound in case of first indication other than Alzheimer disease.

No definition available.

Name:	vygr_CollaborativeArrangementMilestonePaymentsToBeReceivedForLicensedCompoundInCaseOfFirstIndicationOtherThanAlzheimerDisease
Namespace Prefix:	vygr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The amount of milestone payments to be received for licensed compound for subsequent non-Alzheimer's disease indication.

No definition available.

Name:	vygr_CollaborativeArrangementMilestonePaymentsToBeReceivedForLicensedCompoundNonAlzheimerDisease
Namespace Prefix:	vygr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The non-redeemable upfront fee received by the reporting entity from the collaborative partner.

No definition available.

Name:	vygr_CollaborativeArrangementNonredeemableUpFrontFeeReceived
Namespace Prefix:	vygr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Represents the number of additional research compounds under collaborative arrangements.

No definition available.

Name:	vygr_CollaborativeArrangementNumberOfAdditionalResearchCompounds
Namespace Prefix:	vygr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

Represents the amount of one-time payment to be received upon exercise of license option under collaborative arrangements.

No definition available.

Name:	vygr_CollaborativeArrangementOneTimePaymentToBeReceivedUponExerciseOfLicenseOption
Namespace Prefix:	vygr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Represents the number of research compounds to proceed to development period.

No definition available.

Name:	vygr_CollaborativeArrangementResearchCompoundsNumber
Namespace Prefix:	vygr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

Represents the amount of two additional research compounds payments to be received for each under collaborative arrangements.

No definition available.

Name:	vygr_CollaborativeArrangementTwoAdditionalResearchCompoundsPaymentToBeReceivedForEach
Namespace Prefix:	vygr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Number of development options.

No definition available.

Name:	vygr_NumberOfDevelopmentOptions
Namespace Prefix:	vygr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

The number of Licensed Products.

No definition available.

Name:	vygr_NumberOfLicensedProducts
Namespace Prefix:	vygr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

The number of antibodies to include in Research Period per collaboration.

No definition available.

Name:	vygr_PossibleAntibodiesToIncludeInCollaboration
Namespace Prefix:	vygr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_CounterpartyNameAxis=vygr_AbbvieBiotechnologyLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: